ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO887

Prevalence of CKD: Comparison of Real-World Data (RWD) Sources to the US National Health and Nutrition Examination Survey (NHANES)

Session Information

Category: CKD (Non-Dialysis)

  • 2201 CKD (Non-Dialysis): Epidemiology‚ Risk Factors‚ and Prevention

Authors

  • Stavas, Joseph, ProKidney, Raleigh, North Carolina, United States
  • Butler, Emily Lynn, ProKidney, Raleigh, North Carolina, United States
  • Irwin, Debra E., Aetion, New York, New York, United States
  • Shah, Rohan J., Aetion, New York, New York, United States
  • Latimer, Helen, Aetion, New York, New York, United States
  • Sepulveda, Alberto, Royalty Pharma, New York, New York, United States
  • Balkin, Sandy D., Royalty Pharma, New York, New York, United States
  • Tuttle, Katherine R., Providence Health System, Spokane, Washington, United States
Background

NHANES is a common source of CKD prevalence data in the USA, where CKD stage is based on one eGFR estimate using the KDIGO categories. We estimated the prevalence of CKD stage ≥3 using RWD and compared it to NHANES estimates.

Methods

RWD was extracted from HealthVerity PrivateSource20 closed claims and linked to Veradigm Health Insights Electronic Health Record (EHR). Adults, ≥20 years old, continuously enrolled in the claims data and active in the EHR were evaluated during 2018. eGFR values were used to determine the CKD stage. The prevalence of CKD stage ≥3 was projected to the USA population (standardized on age, gender, and geographic region using USA census data) and compared to the NHANES 2015-2018 report.

Results

The prevalence of all CKD stage ≥3 estimated in RWD was significantly lower than NHANES reports (see table). This finding translates into 22.5 million individuals estimated from NHANES and 5.2 million from RWD. The absolute differences between the two groups were less for higher categories.

Conclusion

Prevalence estimates from our RWD sources included those who have continuous health insurance, sought healthcare, and were diagnosed with CKD. In contrast, NHANES sampled a more diverse population likely to be covered by various forms of insurance including the uninsured. This work supports the unmet need for early identification of CKD and demonstrates necessity for methodological clarity when reporting prevalence estimates.

Prevalence of CKD stages
SOURCEStage 3-5Stage 3Stage 4Stage 5
NHANES7%6.4%0.4%0.1%
Real World Data2%*1.8%*0.1%*0.05%*

*p < 0.05

Funding

  • Commercial Support